Technology leaders to jointly explore accessible, high-performance DNA/RNA sequencing solutions powered by Oracle Cloud Infrastructure (OCI) to improve patient care and outcomesAustin, Texas—September 16, 2021
Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology.
Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential new solutions that would use genomic sequencing running on Oracle Cloud Infrastructure (OCI) to help speed medical breakthroughs and improve patient care.
Scientific researchers in more than 100 countries are already using nanopore sequencing to further their understanding of biology in a range of areas including human and cancer genetics as well as plant, animal, and environmental analyses. In addition, nanopore sequencing has been used for pathogen analysis, including the outbreak surveillance of tuberculosis, food-borne pathogens, Ebola, Zika, Lassa fever, dengue fever, influenza, and most recently COVID-19.
As part of the collaboration, Oxford Nanopore will be using OCI in applied and clinical markets. Leveraging the high performance, security, and extensive reach of Oracle Cloud, Oracle and Oxford Nanopore will have the ability to extend population-scale genetic sequencing across the globe.
The organizations will also take on several ambitious projects spanning epidemiology, whole-genome sequencing, and healthcare and drug discovery. This includes integrating Oxford Nanopore’s DNA/RNA sequencing capabilities and data into Oracle’s broad portfolio of healthcare and life sciences applications to strengthen the links between genomics, medical treatment, and drug development.
“Oxford Nanopore’s innovative sequencing technology is unparalleled in the market for its ability to generate rich, accurate genomic data at any scale, from handheld devices to ultra-high output installations,” said Mike Sicilia, executive vice president of Oracle Vertical Industries. “By integrating genomic data into our existing applications and cloud infrastructure solutions, we can get these powerful tools into the hands of more people to solve critical health issues faster and improve patient outcomes to usher in a new era of genomic breakthrough.”
In parallel, Oracle has committed to investing £150 million in Oxford Nanopore, subject to customary conditions.
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.
This press release contains forward-looking statements including, among other things, statements relating to (1) a memorandum of understanding between Oracle and Oxford Nanopore Technologies, whereby the two companies will explore collaboratively a number of potential new solutions to address opportunities in applied and clinical markets and related go-to-market strategies, including Oxford Nanopore Technologies’ migration of its EPI2ME platform to the Oracle Cloud Infrastructure and (2) Oracle’s commitment to invest $150 million in Oxford Nanopore Technologies. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The degree to which the parties collaborate, the migration of the platform and the success of the foregoing, as well as the consummation of the investment, are subject to many factors that could cause actual results to differ materially. A detailed discussion of these factors and other risks that affect our business is contained in our SEC filings, including our most recent reports on Form 10-K and Form 10-Q, particularly under the heading "Risk Factors." All information set forth in this press release is current as of September , 2021. Oracle undertakes no duty to update any statement in light of new information or future events.